Return to study ST001949 main page
MB Sample ID: SA183878
| Local Sample ID: | 6_006 |
| Subject ID: | SU002027 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 21 - 84 |
| Gender: | Male and female |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU002027 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 21 - 84 |
| Gender: | Male and female |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| 6_006 | SA183878 | FL022622 | Control | Condition |
Collection:
| Collection ID: | CO002020 |
| Collection Summary: | Venous blood samples were collected in 8.5 mL ACD Solution A BD Vacutainer tubes for the healthy control, and RA patients prior to initiation of MTX and at a 16 week follow up visit. Venous blood samples were collected and separated into plasma and cellular fractions by centrifugation at 3,000 RPM in a Thermo Scientific Sorvall Legend XTR centrifuge for 10 minutes. The resulting plasma supernatant was separated into aliquots and stored at -80 ⁰C prior to analysis. |
| Sample Type: | Blood (plasma) |
| Storage Conditions: | -80℃ |
| Additives: | ACD |
Treatment:
| Treatment ID: | TR002039 |
| Treatment Summary: | Biobanked plasma samples were acquired from a subset of RA patients (n=20) that participated in a 16-week multicenter open-label study that sought to evaluated predictors of MTX response in RA (ClinicalTrials.gov NCT03414502) (PMID: 32911284). The study included sites within the Rheumatology Arthritis Investigational Network (RAIN). For each patient, plasma samples at baseline and 16-weeks were provided for analysis. All patients received 15 mg/week of MTX and 1 mg/day of folic acid upon enrollment. The MTX does was escalated to 20 mg/week in patients that did not achieve clinical remission by 8 weeks, as tolerated. |
| Treatment Compound: | Methotrexate |
| Treatment Route: | Subcutaneous or Oral |
| Treatment Dose: | 15-20 mg/week |
| Treatment Doseduration: | 16 weeks |
Sample Preparation:
| Sampleprep ID: | SP002033 |
| Sampleprep Summary: | Plasma samples were sent to the West Coast Metabolomics Center and were processed according to laboratory Standard Operating Procedures for samples preparations of blood plasma or serum samples for lipidomic, biogenic amine, and primary metabolomic analysis using a biphasic MeOH/MTBE/Water extraction procedure. The upper organic phase was used for lipidomics analysis and the aqueous phase was used for analysis of primary metabolism and biogenic amines. |
| Sampleprep Protocol Filename: | Biogenic_Amines.Data Processing Lipidomics.Data Processing Primary_Metabolism.Data_Processing |
Combined analysis:
| Analysis ID | AN003173 |
|---|---|
| Analysis type | MS |
| Chromatography type | GC |
| Chromatography system | Leco Pegasus IV |
| Column | Restek Rtx-5Sil (30m x 0.25mm,0.25um) |
| MS Type | EI |
| MS instrument type | GC-TOF |
| MS instrument name | Leco Pegasus IV TOF |
| Ion Mode | POSITIVE |
| Units | Peak Height Intensity |
Chromatography:
| Chromatography ID: | CH002346 |
| Instrument Name: | Leco Pegasus IV |
| Column Name: | Restek Rtx-5Sil (30m x 0.25mm,0.25um) |
| Chromatography Type: | GC |
MS:
| MS ID: | MS002951 |
| Analysis ID: | AN003173 |
| Instrument Name: | Leco Pegasus IV TOF |
| Instrument Type: | GC-TOF |
| MS Type: | EI |
| MS Comments: | MS acquisition, data processing, and feature assignments were conducted at the West Coast Metabolomics Center. Please reference the attached protocols. |
| Ion Mode: | POSITIVE |
